Evidence map›Paper›PMID 41342942›Full record

Observational studyJournal of neurology2025

Anchor-based evaluation of digital motor biomarkers from a 2-year observation in 100 patients with multiple sclerosis.

Carla A Ellinghaus, Hanna M Röhling, Eva-Maria Dorsch, Pia S Sperber, Radina Arsenova, Gilberto Solorza Buenrostro, Sophia Rekers, Tatiana Usnich, Patrick Schindler, Daniel Kroneberg and 7 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04993274 (Sensitivity of Quantitative Motor Performance Measures in Multiple Sclerosis - a Prospective Cohort Study Over Two Years Using Microsoft Kinect), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04993274 unknown statusnot on this map

Sensitivity of Quantitative Motor Performance Measures in Multiple Sclerosis - a Prospective Cohort Study Over Two Years Using Microsoft Kinect

TypeobservationalSponsorFriedemann PaulRan2019 to 2022Enrolled100ConditionsMultiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Chronic ProgressiveArmsPASS-MS
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Carla A EllinghausExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany. carla.ellinghaus@charite.de.ORCID http://orcid.org/0009-0007-6790-656X
Hanna M RöhlingExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Eva-Maria DorschExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Pia S SperberExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Radina ArsenovaExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Gilberto Solorza BuenrostroExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Sophia RekersDepartment of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Tatiana UsnichExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Patrick SchindlerExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Daniel KronebergDepartment of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Judith Bellmann-StroblExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Frederike C OertelExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Alexander U BrandtExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Martin WeygandtExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Friedemann PaulExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.
Sophie K PiperCharité - Universitätsmedizin Berlin, Institute of Biometry and Clinical Epidemiology, Berlin, Germany.
Tanja Schmitz-HübschExperimental and Clinical Research Center (ECRC), a Cooperation of Max-Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Clinical Neuroimmunology Group, Berlin, Germany.

Funding

Roche Pharma AG ML40505
6 · The paper itself

Abstract

backgroundDescription of disease progression in MS lack sensitive clinical outcomes. Digital motor outcomes (DMO) offer potential but require thorough validation.

objectiveThis 2-year observational study explores the sensitivity of 26 DMO derived from a task-based assessment protocol via RGB-D camera.

methodsOne-hundred people with MS (pwMS) were enrolled, 96 completed follow-up. Expanded Disability Status Scale (EDSS) and 12-Item MS Walking Scale (MSWS-12) served as anchors for sensitivity by classifying progression, improvement or stable at 2 years, irrespective of intercurrent relapses. Primary analysis applied linear mixed modeling. Distribution-based thresholds (MDC) were calculated from stable subgroups.

resultsSix DMO showed a significant increase over time in relation to stand-up/sit-movement (β = 0.01; β = 0.02), stepping asymmetry (β = 0.02; β = 0.02), trunk deflection while walking (β = 0.02) and trunk sway in closed-eyes stance (β = 0.02) (95% CI 0.001-0.038; all p < 0.05). EDSS (n = 22) and MSWS-12 (n = 11) progression groups were distinct. Time effects differed by anchor. For the EDSS progression group, the change in step width and sway velocity in closed-feet/open-eyes stance exceeded measurement error.

conclusionsOur findings yield a well-applicable set of DMO that may support definitions of disability accumulation in (early) pwMS. Establishing patient relevance remains challenging due to expectedly low clinical progression rates. The distinct patterns captured by EDSS and MSWS-12 definitions underline the need for multiple anchors when validating new biomarkers. Trial registration ClinicalTrials.gov, NCT04993274, 2021-03-09 retrospectively registered.

Indexed as

Multiple SclerosisAdultBiomarkersDisability EvaluationDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedSeverity of Illness IndexBiomarkersBiomarkersDigital motor outcomesDisease monitoringMinimal detectable changeMultiple sclerosisProgression

Identifiers

PMID41342942
PMCPMC12678454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.